Skip to main content
Top
Published in: BMC Neurology 1/2010

Open Access 01-12-2010 | Research article

Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism

Authors: Niklas Mattsson, Daniel Bremell, Rolf Anckarsäter, Kaj Blennow, Henrik Anckarsäter, Henrik Zetterberg, Lars Hagberg

Published in: BMC Neurology | Issue 1/2010

Login to get access

Abstract

Background

The metabolism of amyloid precursor protein (APP) and β-amyloid (Aβ) is widely studied in Alzheimer's disease, where Aβ deposition and plaque development are essential components of the pathogenesis. However, the physiological role of amyloid in the adult nervous system remains largely unknown. We have previously found altered cerebral amyloid metabolism in other neuroinflammatory conditions. To further elucidate this, we investigated amyloid metabolism in patients with Lyme neuroborreliosis (LNB).

Methods

The first part of the study was a cross-sectional cohort study in 61 patients with acute facial palsy (19 with LNB and 42 with idiopathic facial paresis, Bell's palsy) and 22 healthy controls. CSF was analysed for the β-amyloid peptides Aβ38, Aβ40 and Aβ42, and the amyloid precursor protein (APP) isoforms α-sAPP and β-sAPP. CSF total-tau (T-tau), phosphorylated tau (P-tau) and neurofilament protein (NFL) were measured to monitor neural cell damage. The second part of the study was a prospective cohort-study in 26 LNB patients undergoing consecutive lumbar punctures before and after antibiotic treatment to study time-dependent dynamics of the biomarkers.

Results

In the cross-sectional study, LNB patients had lower levels of CSF α-sAPP, β-sAPP and P-tau, and higher levels of CSF NFL than healthy controls and patients with Bell's palsy. In the prospective study, LNB patients had low levels of CSF α-sAPP, β-sAPP and P-tau at baseline, which all increased towards normal at follow-up.

Conclusions

Amyloid metabolism is altered in LNB. CSF levels of α-sAPP, β-sAPP and P-tau are decreased in acute infection and increase after treatment. In combination with earlier findings in multiple sclerosis, cerebral SLE and HIV with cerebral engagement, this points to an influence of neuroinflammation on amyloid metabolism.
Appendix
Available only for authorised users
Literature
1.
go back to reference Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet. 2006, 368 (9533): 387-403. 10.1016/S0140-6736(06)69113-7.CrossRefPubMed Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet. 2006, 368 (9533): 387-403. 10.1016/S0140-6736(06)69113-7.CrossRefPubMed
2.
go back to reference Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, et al: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008, 65 (8): 1102-1107. 10.1001/archneur.65.8.1102.CrossRefPubMed Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, et al: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008, 65 (8): 1102-1107. 10.1001/archneur.65.8.1102.CrossRefPubMed
3.
go back to reference Mattsson N, Axelsson M, Haghighi S, Malmestrom C, Wu G, Anckarsater R, Sankaranarayanan S, Andreasson U, Fredrikson S, Gundersen A, et al: Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler. 2009, 15 (4): 448-454. 10.1177/1352458508100031.CrossRefPubMed Mattsson N, Axelsson M, Haghighi S, Malmestrom C, Wu G, Anckarsater R, Sankaranarayanan S, Andreasson U, Fredrikson S, Gundersen A, et al: Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler. 2009, 15 (4): 448-454. 10.1177/1352458508100031.CrossRefPubMed
4.
go back to reference Gisslen M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, Spudich S, Hagberg L, Rosengren L, Price RW, et al: Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol. 2009, 9 (1): 63-10.1186/1471-2377-9-63.CrossRefPubMedPubMedCentral Gisslen M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, Spudich S, Hagberg L, Rosengren L, Price RW, et al: Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol. 2009, 9 (1): 63-10.1186/1471-2377-9-63.CrossRefPubMedPubMedCentral
5.
go back to reference Pachner AR, Steiner I: Lyme neuroborreliosis: infection, immunity, and inflammation. Lancet Neurol. 2007, 6 (6): 544-552. 10.1016/S1474-4422(07)70128-X.CrossRefPubMed Pachner AR, Steiner I: Lyme neuroborreliosis: infection, immunity, and inflammation. Lancet Neurol. 2007, 6 (6): 544-552. 10.1016/S1474-4422(07)70128-X.CrossRefPubMed
6.
7.
go back to reference Anckarsater R, Vasic N, Jideus L, Kristiansson M, Zetterberg H, Blennow K, Anckarsater H: Cerebrospinal fluid protein reactions during non-neurological surgery. Acta Neurol Scand. 2007, 115 (4): 254-259. 10.1111/j.1600-0404.2006.00741.x.CrossRefPubMed Anckarsater R, Vasic N, Jideus L, Kristiansson M, Zetterberg H, Blennow K, Anckarsater H: Cerebrospinal fluid protein reactions during non-neurological surgery. Acta Neurol Scand. 2007, 115 (4): 254-259. 10.1111/j.1600-0404.2006.00741.x.CrossRefPubMed
8.
go back to reference Dotevall L, Hagberg L: Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis. 1999, 28 (3): 569-574. 10.1086/515145.CrossRefPubMed Dotevall L, Hagberg L: Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis. 1999, 28 (3): 569-574. 10.1086/515145.CrossRefPubMed
9.
go back to reference Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol. 1995, 26 (3): 231-245. 10.1007/BF02815140.CrossRefPubMed Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol. 1995, 26 (3): 231-245. 10.1007/BF02815140.CrossRefPubMed
10.
go back to reference Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000, 285 (1): 49-52. 10.1016/S0304-3940(00)01036-3.CrossRefPubMed Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000, 285 (1): 49-52. 10.1016/S0304-3940(00)01036-3.CrossRefPubMed
11.
go back to reference Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996, 67 (5): 2013-2018. 10.1046/j.1471-4159.1996.67052013.x.CrossRefPubMed Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996, 67 (5): 2013-2018. 10.1046/j.1471-4159.1996.67052013.x.CrossRefPubMed
12.
go back to reference Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med. 2006, 12 (9): 1005-1015.PubMed Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med. 2006, 12 (9): 1005-1015.PubMed
13.
go back to reference Schlachetzki JC, Hull M: Microglial activation in Alzheimer's disease. Curr Alzheimer Res. 2009, 6 (6): 554-563. 10.2174/156720509790147179.CrossRefPubMed Schlachetzki JC, Hull M: Microglial activation in Alzheimer's disease. Curr Alzheimer Res. 2009, 6 (6): 554-563. 10.2174/156720509790147179.CrossRefPubMed
14.
go back to reference Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Moller HJ, Hampel H, Davidsson P, et al: Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol. 2003, 183 (1): 74-80. 10.1016/S0014-4886(03)00027-X.CrossRefPubMed Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Moller HJ, Hampel H, Davidsson P, et al: Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol. 2003, 183 (1): 74-80. 10.1016/S0014-4886(03)00027-X.CrossRefPubMed
15.
go back to reference Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L, Wolf S, et al: Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry. 15 (2): 138-145. 10.1038/mp.2008.84. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L, Wolf S, et al: Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry. 15 (2): 138-145. 10.1038/mp.2008.84.
16.
go back to reference Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L: CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology. 2005, 65 (9): 1490-1492. 10.1212/01.wnl.0000183293.95787.b7.CrossRefPubMed Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L: CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology. 2005, 65 (9): 1490-1492. 10.1212/01.wnl.0000183293.95787.b7.CrossRefPubMed
17.
go back to reference Sjogren M, Gisslen M, Vanmechelen E, Blennow K: Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci Lett. 2001, 314 (12): 33-36. 10.1016/S0304-3940(01)02285-6.CrossRefPubMed Sjogren M, Gisslen M, Vanmechelen E, Blennow K: Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci Lett. 2001, 314 (12): 33-36. 10.1016/S0304-3940(01)02285-6.CrossRefPubMed
18.
go back to reference Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999, 56 (6): 673-680. 10.1001/archneur.56.6.673.CrossRefPubMed Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999, 56 (6): 673-680. 10.1001/archneur.56.6.673.CrossRefPubMed
19.
go back to reference Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, Cepek L, Zerr I, Steinacker P, Windl O, et al: Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology. 2000, 54 (5): 1099-1102.CrossRefPubMed Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, Cepek L, Zerr I, Steinacker P, Windl O, et al: Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology. 2000, 54 (5): 1099-1102.CrossRefPubMed
20.
go back to reference Weller RO: How well does the CSF inform upon pathology in the brain in Creutzfeldt-Jakob and Alzheimer's diseases?. J Pathol. 2001, 194 (1): 1-3. 10.1002/1096-9896(200105)194:1<1::AID-PATH871>3.0.CO;2-M.CrossRefPubMed Weller RO: How well does the CSF inform upon pathology in the brain in Creutzfeldt-Jakob and Alzheimer's diseases?. J Pathol. 2001, 194 (1): 1-3. 10.1002/1096-9896(200105)194:1<1::AID-PATH871>3.0.CO;2-M.CrossRefPubMed
21.
go back to reference Sanchez-Alavez M, Chan SL, Mattson MP, Criado JR: Electrophysiological and cerebrovascular effects of the alpha-secretase-derived form of amyloid precursor protein in young and middle-aged rats. Brain Res. 2007, 1131 (1): 112-117. 10.1016/j.brainres.2006.10.074.CrossRefPubMed Sanchez-Alavez M, Chan SL, Mattson MP, Criado JR: Electrophysiological and cerebrovascular effects of the alpha-secretase-derived form of amyloid precursor protein in young and middle-aged rats. Brain Res. 2007, 1131 (1): 112-117. 10.1016/j.brainres.2006.10.074.CrossRefPubMed
22.
go back to reference Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009, 457 (7232): 981-989. 10.1038/nature07767.CrossRefPubMedPubMedCentral Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009, 457 (7232): 981-989. 10.1038/nature07767.CrossRefPubMedPubMedCentral
23.
go back to reference Dotevall L, Hagberg L, Karlsson JE, Rosengren LE: Astroglial and neuronal proteins in cerebrospinal fluid as markers of CNS involvement in Lyme neuroborreliosis. Eur J Neurol. 1999, 6 (2): 169-178. 10.1111/j.1468-1331.1999.tb00010.x.CrossRefPubMed Dotevall L, Hagberg L, Karlsson JE, Rosengren LE: Astroglial and neuronal proteins in cerebrospinal fluid as markers of CNS involvement in Lyme neuroborreliosis. Eur J Neurol. 1999, 6 (2): 169-178. 10.1111/j.1468-1331.1999.tb00010.x.CrossRefPubMed
24.
go back to reference Hengge UR, Tannapfel A, Tyring SK, Erbel R, Arendt G, Ruzicka T: Lyme borreliosis. Lancet Infect Dis. 2003, 3 (8): 489-500. 10.1016/S1473-3099(03)00722-9.CrossRefPubMed Hengge UR, Tannapfel A, Tyring SK, Erbel R, Arendt G, Ruzicka T: Lyme borreliosis. Lancet Infect Dis. 2003, 3 (8): 489-500. 10.1016/S1473-3099(03)00722-9.CrossRefPubMed
25.
go back to reference Studahl M, Rosengren L, Gunther G, Hagberg L: Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J Neurol. 2000, 247 (8): 636-642. 10.1007/s004150070134.CrossRefPubMed Studahl M, Rosengren L, Gunther G, Hagberg L: Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J Neurol. 2000, 247 (8): 636-642. 10.1007/s004150070134.CrossRefPubMed
26.
go back to reference Trojanowski JQ, Schuck T, Schmidt ML, Lee VM: Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem. 1989, 37 (2): 209-215.CrossRefPubMed Trojanowski JQ, Schuck T, Schmidt ML, Lee VM: Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem. 1989, 37 (2): 209-215.CrossRefPubMed
27.
go back to reference Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, Skoog I, Wallin A, Wahlund LO, Marcusson J, et al: Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem. 2001, 47 (10): 1776-1781.PubMed Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, Skoog I, Wallin A, Wahlund LO, Marcusson J, et al: Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem. 2001, 47 (10): 1776-1781.PubMed
Metadata
Title
Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism
Authors
Niklas Mattsson
Daniel Bremell
Rolf Anckarsäter
Kaj Blennow
Henrik Anckarsäter
Henrik Zetterberg
Lars Hagberg
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2010
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-10-51

Other articles of this Issue 1/2010

BMC Neurology 1/2010 Go to the issue